About this trial

The purpose of this study is to analyze patterns in individuals with hnRNP (and other) genetic variants, including their neurological comorbidities, other medical problems and any treatment. The investigators will maintain an ongoing database of medical data that is otherwise being collected for routine medical care. The investigators will also collect data prospectively in the form of questionnaires, neuropsychological assessments, motor assessments, and electroencephalography to examine the landscape of deleterious variants in these genes.

Eligibility criteria

Qualifiers

Individuals must have had whole genome/exome sequencing and have a confirmed variant in any gene.

Disqualifiers

Subjects who cannot provide genetic confirmation of a predicted deleterious variant in any gene.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,000 Participants
are grouped into 2 trial groups

Locations

1
Columbia University Irving Medical Center10032, New YorkNew York, United States

Sponsors and collaborators

Columbia University

Lead sponsor

Simons Foundation

Collaborator

New York University

Collaborator

Hackensack Meridian Health

Collaborator

Universitätsklinikum Hamburg-Eppendorf

Collaborator